Skip to main content

NIH Archives

Team studies new use for pulmonary hypertension drug

Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

Read more


Prostate cancer microenvironment

Mar. 23, 2021—Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

Read more


Chemo for cancer lowers dementia risk

Mar. 22, 2021—Cancer chemotherapy lowered risk of Alzheimer’s disease and other neurocognitive disorders that disproportionately affect older people.

Read more


Strength training for osteoarthritis

Mar. 18, 2021—High-intensity strength training is not more effective than low-intensity training or educational efforts for reducing knee pain in patients with osteoarthritis.

Read more


HIV, diabetes and immune cells in fat

Mar. 18, 2021—In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

Read more


Electronic health record study discovers novel hormone deficiency

Mar. 11, 2021—A novel hormone deficiency may exist in humans, Vanderbilt investigators have discovered. In an analysis of two decades worth of electronic health records, the researchers found that some patients have unexpectedly low levels of natriuretic peptide hormone in clinical situations that should cause high levels of the hormone.

Read more


Markers for breast cancer progression

Mar. 9, 2021—Vanderbilt researchers clarify how a microRNA associated with triple-negative breast cancer survival inhibits cancer progression, suggesting new treatment strategies.

Read more


Probiotic protection

Mar. 4, 2021—A probiotic factor given early in life to mice prevented intestinal inflammation in adulthood, providing a rationale for probiotic intervention in individuals at high risk of developing inflammatory bowel disease.

Read more


Targeting glucagon action in diabetes

Mar. 4, 2021—Disrupting the action of glucagon — a pancreatic hormone that works to raise blood glucose — restores functional insulin-producing cells in mouse models of type 1 diabetes and may be a promising treatment strategy.

Read more


Calcification after severe injury

Feb. 23, 2021—Vanderbilt researchers have linked bone-related complications of severely injured patients — findings that could help minimize these complications.

Read more


Gene variant and glucose metabolism

Feb. 18, 2021—Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study.

Read more


Clinical Trials Unit lands major grant renewal

Feb. 11, 2021—Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have received renewal of a major federal grant to continue their collaboration to test and develop new treatments and vaccines against HIV/AIDS — and now COVID-19.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more